Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Long-Term Deferred Tax (2023 - 2025)

Ascendis Pharma A's Long-Term Deferred Tax history spans 1 years, with the latest figure at -$6.3 million for Q4 2023.

  • For Q4 2023, Long-Term Deferred Tax changed N/A year-over-year to -$6.3 million; the TTM value through Dec 2023 reached -$6.3 million, changed N/A, while the annual FY2023 figure was -$6.3 million, N/A changed from the prior year.
  • Long-Term Deferred Tax for Q4 2023 was -$6.3 million at Ascendis Pharma A.
  • Across five years, Long-Term Deferred Tax topped out at -$6.3 million in Q4 2023 and bottomed at -$6.3 million in Q4 2023.